Skandinaviska Enskilda Banken (SEB) Portfolio holdings
AUM
$23B
1-Year Return
23.43%
This Quarter Return
+5.57%
1 Year Return
+23.43%
3 Year Return
+116.09%
5 Year Return
+203.29%
10 Year Return
–
AUM
$20.8B
AUM Growth
+$384M
(+1.9%)
Cap. Flow
-$460M
Cap. Flow
% of AUM
-2.21%
Top 10 Holdings %
Top 10 Hldgs %
36.66%
Holding
834
New
50
Increased
348
Reduced
209
Closed
64
Top Buys
| 1 |
Microsoft
MSFT
|
$339M |
| 2 |
Progressive
PGR
|
$111M |
| 3 |
Cigna
CI
|
$101M |
| 4 |
Qualcomm
QCOM
|
$95.5M |
| 5 |
JPMorgan Chase
JPM
|
$75.9M |
Top Sells
| 1 |
Alphabet (Google) Class A
GOOGL
|
$335M |
| 2 |
Alphabet (Google) Class C
GOOG
|
$222M |
| 3 |
NVIDIA
NVDA
|
$201M |
| 4 |
Booking.com
BKNG
|
$104M |
| 5 |
Meta Platforms (Facebook)
META
|
$88.5M |
Sector Composition
| 1 | Technology | 38.73% |
| 2 | Healthcare | 17.07% |
| 3 | Financials | 10.41% |
| 4 | Consumer Discretionary | 9.88% |
| 5 | Communication Services | 9.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SRCL
626
DELISTED
Stericycle Inc
SRCL
| $1.16M | 0.01% |
+20,000
| New | +$1.16M |
|
627
Revolution Medicines
RVMD
$7.57B
| $1.15M | 0.01% |
29,705
| – | – |
|
628
IDEAYA Biosciences
IDYA
$2.38B
| $1.14M | 0.01% |
32,544
| – | – |
|
629
Kymera Therapeutics
KYMR
$3.11B
| $1.14M | 0.01% |
38,141
| – | – |
|
630
Mobileye
MBLY
$12B
| $1.13M | 0.01% |
40,257
+14,300
| +55% | +$402K |
|
631
GitLab
GTLB
$7.63B
| $1.12M | 0.01% |
+22,409
| New | +$1.12M |
|
632
Huazhu Hotels Group
HTHT
$11.5B
| $1.11M | 0.01% |
33,400
-90,700
| -73% | -$3.02M |
|
633
Franklin Resources
BEN
$13B
| $1.11M | 0.01% |
49,545
| – | – |
|
634
Kura Oncology
KURA
$713M
| $1.11M | 0.01% |
53,738
| – | – |
|
|
PARA
635
DELISTED
Paramount Global Class B
PARA
| $1.09M | 0.01% |
104,904
+5,400
| +5% | +$56.1K |
|
636
Adtran
ADTN
$781M
| $1.07M | 0.01% |
204,261
+36,371
| +22% | +$191K |
|
637
Pan American Silver
PAAS
$14.6B
| $1.06M | 0.01% |
53,557
+328
| +0.6% | +$6.52K |
|
638
Gildan
GIL
$8.27B
| $1.06M | 0.01% |
27,901
| – | – |
|
639
Bio-Rad Laboratories Class A
BIO
$8B
| $1.05M | 0.01% |
3,831
| – | – |
|
640
Southwest Airlines
LUV
$16.5B
| $1.01M | ﹤0.01% |
35,405
| – | – |
|
641
Itron
ITRI
$5.51B
| $1.01M | ﹤0.01% |
10,207
+5,047
| +98% | +$500K |
|
642
Denali Therapeutics
DNLI
$2.26B
| $1M | ﹤0.01% |
43,245
| – | – |
|
643
Janux Therapeutics
JANX
$1.44B
| $989K | ﹤0.01% |
23,617
| – | – |
|
644
Axcelis
ACLS
$2.53B
| $983K | ﹤0.01% |
6,902
+1,039
| +18% | +$148K |
|
645
Apellis Pharmaceuticals
APLS
$3.55B
| $982K | ﹤0.01% |
25,581
| – | – |
|
646
Shoals Technologies Group
SHLS
$1.2B
| $980K | ﹤0.01% |
157,000
+93,400
| +147% | +$583K |
|
647
4D Molecular Therapeutics
FDMT
$340M
| $936K | ﹤0.01% |
44,600
| – | – |
|
648
AbCellera Biologics
ABCL
$1.26B
| $913K | ﹤0.01% |
308,567
+158,000
| +105% | +$468K |
|
649
Iovance Biotherapeutics
IOVA
$901M
| $912K | ﹤0.01% |
113,952
| – | – |
|
650
Grab
GRAB
$21B
| $869K | ﹤0.01% |
244,903
+110
| +0% | +$391 |
|